A Phase 2 interventional study of Carfilzomib in Multiple Myeloma and Renal Insufficiency, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 60th largest by enrollment, is one of 2 that started in 2008, is one of 50 in phase 2, and was the 6th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2008, is one of 10 in phase 2, and was the 10th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current , as indicated by one or more of the following:
≥ 7 gm/dL
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles. If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles.
Drug: Carfilzomib
Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
Also known as: PR-171, Kyprolis®
Clearance (CL) of Carfilzomib on Day 1 of Cycle 1
Plasma concentrations of carfilzomib was determined by a validated liquid chromatography tandem mass spectrometry (LC MS/MS) method. The lower limit of quantitation (LLOQ) was 0.300 ng/mL. Concentration values that were below the LLOQ (BLQ) were set to zero. Pharmacokinetic (PK) parameters were calculated from the individual plasma concentrations of carfilzomib using a noncompartmental method.
Time frame: Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Clearance (CL) of Carfilzomib on Day 15 of Cycle 1
Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Clearance (CL) of Carfilzomib on Day 15 of Cycle 2
Time frame: Cycle 2, Day 15, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1
Time frame: Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1
Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2
Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1
Time frame: Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1
Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2
Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1
Time frame: Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1
Time frame: Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2
Time frame: Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1
The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.
Time frame: Cycle 1, Day 1, 0-5 and 5-24 hours post-dose
Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1
The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.
Time frame: Cycle 1, Day 15, 0-5 and 5-24 hours post-dose
Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1
The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.
Time frame: Cycle 1, Day 1, 0-5 and 5-24 hours post-dose
Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1
The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.
Time frame: Cycle 1, Day 15, 0-5 and 5-24 hours post-dose
Plasma Protein Binding (PPB) of Carfilzomib
The plasma protein binding (PPB) of carfilzomib in plasma samples was determined using a rapid equilibrium dialysis (RED) device. Data are averages of the 3 time points (Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15).
Time frame: End of injection and 5 minutes post-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15
Overall Response Rate (ORR)
ORR is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Uniform Response Criteria for Multiple Myeloma. sCR: CR as defined below plus normal serum free light chain (sFLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or immunofluorescence; CR: absence of M-protein in serum and urine confirmed by immunofixation and \< 5% plasma cells in the bone marrow; VGPR: serum and urine M-proteins detectable by immunofixation, but not by electrophoresis or a ≥ 90% reduction in serum M-protein from baseline, plus a urine M-protein level of \< 100 mg/24 hours; PR: reduction of M-protein in serum of ≥ 50% and in urine of ≥ 90% from baseline. If serum and urine M-protein were not measureable at baseline, a ≥ 50% decrease in the difference between involved and uninvolved sFLC levels from baseline.
Time frame: From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.
Clinical Benefit Rate (CBR)
Clinical benefit rate is defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89% from baseline, maintained for at least 6 weeks.
Time frame: From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.
Duration of Response
Duration of Response is defined as the time from first evidence of PR or better to confirmation of disease progression or death. Progressive disease was defined as any of the following: * An increase of more than 25% from nadir in any one of the following: * M-protein in serum (the absolute increase had to be ≥ 0.5 g/dL); * Urine (the absolute increase had to be ≥ 200 mg/24 hours); * The difference between involved and uninvolved sFLC (the absolute increase in the concentration of involved light chain had to be \> 10 mg/dL); * ≥ 10% bone marrow infiltration by plasma cells; * Increased size of pre-existing bone lesions or plasmacytomas or new bone lesions or plasmacytomas. Median duration of response was estimated using the Kaplan-Meier method.
Time frame: Participants were followed for disease progression for up to 2 years.
Time to Progression (TTP)
Time to Progression is defined as the time from first dose of carfilzomib to disease progression. Median TTP was estimated using Kaplan-Meier methods.
Time frame: Participants were followed for disease progression for up to 2 years.
This study enrolled patients with multiple myeloma (MM) who had relapsed or progressive disease (PD) after at least 1 (original protocol) or 2 (following protocol Amendment 1) prior therapeutic treatments or regimens. Five groups of MM patients, representing different levels of renal function, were evaluated.
| Milestone | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Started | 12 | 12 | 10 | 8 | 8 |
| Completed | 4 | 0 | 2 | 2 | 2 |
| Not completed | 8 | 12 | 8 | 6 | 6 |
| Withdrew: Progressive disease | 3 | 10 | 4 | 5 | 2 |
| Withdrew: Adverse event | 3 | 1 | 4 | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
Plasma concentrations of carfilzomib was determined by a validated liquid chromatography tandem mass spectrometry (LC MS/MS) method. The lower limit of quantitation (LLOQ) was 0.300 ng/mL. Concentration values that were below the LLOQ (BLQ) were set to zero. Pharmacokinetic (PK) parameters were calculated from the individual plasma concentrations of carfilzomib using a noncompartmental method.
| liters/hour | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Clearance (CL) of Carfilzomib on Day 1 of Cycle 1 | 151 ± 79.3 | 113 ± 40.7 | 288 ± 264 | 170 ± 58.4 | 170 ± 60.2 |
| liters/hour | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Clearance (CL) of Carfilzomib on Day 15 of Cycle 1 | 660 ± 1134 | 115 ± 34.7 | 119 ± 16.5 | 110 ± NA | 114 ± 61.2 |
| liters/hour | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Clearance (CL) of Carfilzomib on Day 15 of Cycle 2 | — | — | 679 ± NA | 46.6 ± NA | — |
| ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1 | 2077 ± 91.4 | 1623 ± 161 | 1840 ± 92.4 | 1231 ± 139 | 1539 ± 92.7 |
| ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1 | 1768 ± 179 | 2406 ± 52.3 | 2627 ± 31.8 | 1914 ± 99.8 | 3236 ± 34.4 |
| ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2 | — | — | 244 ± NA | 3064 ± 3.9 | — |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1 | 233 ± 51.6 | 241 ± 32.4 | 145 ± 111 | 172 ± 35.6 | 193 ± 55.2 |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1 | 127 ± 240 | 236 ± 44.3 | 257 ± 10.9 | 218 ± NA | 272 ± 46.4 |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2 | — | — | 48.6 ± NA | 579 ± NA | — |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1 | 187 ± 75.3 | 194 ± 67.6 | 199 ± 91.3 | 135 ± 65.5 | 195 ± 65.3 |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1 | 159 ± 186 | 289 ± 58.5 | 371 ± 55.2 | 343 ± 53.1 | 264 ± 41.7 |
| hr*ng/mL | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2 | — | — | 47.3 ± NA | 345 ± 83.6 | — |
The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.
| percentage of carfilzomib dose | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1 | 0.490 ± 0.316 | 0.429 ± 0.271 | 0.160 ± 0.101 | 0.226 ± 0.0921 | — |
The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose.
| percentage of carfilzomib dose | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1 | 0.446 ± 0.357 | 0.428 ± 0.262 | 0.202 ± 0.116 | 0.168 ± 0.0670 | — |
The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.
| percentage of carfilzomib dose | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| M14 | 33.1 ± 13.1 | 25.0 ± 4.81 | 21.7 ± 7.59 | 19.2 ± 4.36 | — |
| M15 | 1.93 ± 1.12 | 1.42 ± 0.314 | 0.776 ± 0.387 | 0.578 ± 0.230 | — |
The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose.
| percentage of carfilzomib dose | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| M14 | 30.6 ± 11.6 | 27.0 ± 8.47 | 22.0 ± 6.89 | 17.0 ± 4.67 | — |
| M15 | 1.91 ± 1.03 | 1.55 ± 0.602 | 0.856 ± 0.377 | 0.475 ± 0.249 | — |
The plasma protein binding (PPB) of carfilzomib in plasma samples was determined using a rapid equilibrium dialysis (RED) device. Data are averages of the 3 time points (Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15).
| percentage of carfilzomib bound | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| End of Injection | 97.8 ± 0.6 | 97.6 ± 1.5 | 98.4 ± 0.4 | 98.2 ± 0.5 | 97.6 ± 0.7 |
| 5 minutes after injection | 98.1 ± 0.5 | 97.6 ± 1.6 | 98.2 ± 1.5 | 98.1 ± 0.8 | 98.2 ± 0.4 |
ORR is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Uniform Response Criteria for Multiple Myeloma. sCR: CR as defined below plus normal serum free light chain (sFLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or immunofluorescence; CR: absence of M-protein in serum and urine confirmed by immunofixation and \< 5% plasma cells in the bone marrow; VGPR: serum and urine M-proteins detectable by immunofixation, but not by electrophoresis or a ≥ 90% reduction in serum M-protein from baseline, plus a urine M-protein level of \< 100 mg/24 hours; PR: reduction of M-protein in serum of ≥ 50% and in urine of ≥ 90% from baseline. If serum and urine M-protein were not measureable at baseline, a ≥ 50% decrease in the difference between involved and uninvolved sFLC levels from baseline.
| percentage of participants | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 18.2 (2.3 to 51.8) | 27.3 (6.0 to 61.0) | 22.2 (2.8 to 60.0) | 25.0 (3.2 to 65.1) | 37.5 (8.5 to 75.5) |
Clinical benefit rate is defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89% from baseline, maintained for at least 6 weeks.
| percentage of participants | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 27.3 (6.0 to 61.0) | 36.4 (10.9 to 69.2) | 22.2 (2.8 to 60.0) | 37.5 (8.5 to 75.5) | 37.5 (8.5 to 75.5) |
Duration of Response is defined as the time from first evidence of PR or better to confirmation of disease progression or death. Progressive disease was defined as any of the following: * An increase of more than 25% from nadir in any one of the following: * M-protein in serum (the absolute increase had to be ≥ 0.5 g/dL); * Urine (the absolute increase had to be ≥ 200 mg/24 hours); * The difference between involved and uninvolved sFLC (the absolute increase in the concentration of involved light chain had to be \> 10 mg/dL); * ≥ 10% bone marrow infiltration by plasma cells; * Increased size of pre-existing bone lesions or plasmacytomas or new bone lesions or plasmacytomas. Median duration of response was estimated using the Kaplan-Meier method.
| months | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Duration of Response | NA (2.0 to NA) | NA (4.2 to NA) | 14.8 (2.3 to 27.4) | NA (7.9 to NA) | 7.9 (6.5 to 8.5) |
Time to Progression is defined as the time from first dose of carfilzomib to disease progression. Median TTP was estimated using Kaplan-Meier methods.
| months | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| Time to Progression (TTP) | 4.4 (2.8 to 9.2) | 5.6 (0.5 to 7.9) | 2.8 (1.0 to 29.2) | 9.6 (1.0 to 11.8) | 6.5 (2.8 to 11.3) |
Collected over From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 121 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carfilzomib - Normal RF | — | 5/12 (41.7%) | 12/12 (100%) |
| Carfilzomib - Mild RI | — | 8/12 (66.7%) | 12/12 (100%) |
| Carfilzomib - Moderate RI | — | 10/10 (100%) | 10/10 (100%) |
| Carfilzomib - Severe RI | — | 6/8 (75%) | 8/8 (100%) |
| Carfilzomib - Dialysis | — | 8/8 (100%) | 8/8 (100%) |
| Event | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 2/12 | 2/12 | 4/10 | 2/8 | 0/8 |
| Disease progressionGeneral disorders | 0/12 | 3/12 | 0/10 | 1/8 | 3/8 |
| Mental status changesPsychiatric disorders | 0/12 | 1/12 | 3/10 | 0/8 | 0/8 |
| Cardiac failure congestiveCardiac disorders | 1/12 | 0/12 | 0/10 | 2/8 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 0/12 | 0/12 | 2/10 | 2/8 | 0/8 |
| Renal failure acuteRenal and urinary disorders | 0/12 | 1/12 | 1/10 | 2/8 | 0/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/12 | 1/12 | 0/10 | 0/8 | 2/8 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 1/10 | 0/8 | 2/8 |
| InfluenzaInfections and infestations | 0/12 | 0/12 | 2/10 | 0/8 | 1/8 |
| Renal failureRenal and urinary disorders | 0/12 | 0/12 | 2/10 | 0/8 | 0/8 |
| Event | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 9/12 | 9/12 | 6/10 | 4/8 | 4/8 |
| AnaemiaBlood and lymphatic system disorders | 6/12 | 7/12 | 7/10 | 5/8 | 5/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/12 | 6/12 | 5/10 | 3/8 | 5/8 |
| NauseaGastrointestinal disorders | 6/12 | 4/12 | 6/10 | 1/8 | 4/8 |
| LymphopeniaBlood and lymphatic system disorders | 4/12 | 4/12 | 2/10 | 2/8 | 4/8 |
| Abdominal painGastrointestinal disorders | 1/12 | 2/12 | 2/10 | 0/8 | 4/8 |
| ConstipationGastrointestinal disorders | 3/12 | 6/12 | 5/10 | 2/8 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 5/12 | 6/12 | 5/10 | 2/8 | 4/8 |
| PainGeneral disorders | 0/12 | 3/12 | 4/10 | 0/8 | 4/8 |
| PyrexiaGeneral disorders | 3/12 | 2/12 | 3/10 | 0/8 | 4/8 |
| Age, Categorical(Participants) | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 8 | 4 | 1 | 7 | 26 |
| >=65 years | 6 | 4 | 6 | 7 | 1 | 24 |
| Age, Continuous(years) | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis | Total |
|---|---|---|---|---|---|---|
| Mean | 64.5 ± 5.70 | 63.5 ± 7.85 | 66.2 ± 9.65 | 73.0 ± 8.23 | 56.0 ± 7.91 | 64.6 ± 9.01 |
| Sex: Female, Male(Participants) | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 8 | 3 | 3 | 4 | 22 |
| Male | 8 | 4 | 7 | 5 | 4 | 28 |
| Race/Ethnicity, Customized(participants) | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis | Total |
|---|---|---|---|---|---|---|
| African American | 2 | 2 | 4 | 1 | 2 | 11 |
| Asian/Pacific Islander | 0 | 2 | 0 | 0 | 1 | 3 |
| Caucasian | 10 | 8 | 6 | 7 | 5 | 36 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Carfilzomib - Normal RF | Carfilzomib - Mild RI | Carfilzomib - Moderate RI | Carfilzomib - Severe RI | Carfilzomib - Dialysis | Total |
|---|---|---|---|---|---|---|
| 0 (Fully active) | 4 | 2 | 0 | 2 | 0 | 8 |
| 1 (Restrictive but ambulatory) | 8 | 9 | 9 | 1 | 5 | 32 |
| 2 (Ambulatory but unable to work) | 0 | 1 | 1 | 5 | 3 | 10 |
The record gives a start of Nov 2008, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib